More tools:Markets·Screener·Research·Chat

Dogwood Therapeutics, Inc. Common Stock (DWTX) Financial Statements

Dogwood Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00X0SZLB8
XNAS · usd
2.04▼ 0.25 (-10.92%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close2.29
Day's Range2.04 – 2.34
52-Week Range1.28 – 9.50
Volume75.2K
Avg Volume67.1K
Share Statistics
Shares Outstanding
Employees8
ExchangeXNAS
Listed2020-12-17
Share count as of August 13, 2026
Loading Income Statement…
Key questions about Dogwood Therapeutics, Inc. Common Stock (DWTX)
What is Dogwood Therapeutics, Inc. Common Stock's Market Cap?
Dogwood Therapeutics, Inc. Common Stock's Market Cap is $69.3M, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's Enterprise Value?
Dogwood Therapeutics, Inc. Common Stock's Enterprise Value is $59.7M, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's EV / EBITDA?
Dogwood Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's Net Income (TTM)?
Dogwood Therapeutics, Inc. Common Stock's Net Income (TTM) is -$36.0M, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's EBITDA?
Dogwood Therapeutics, Inc. Common Stock's EBITDA is -$38.8M, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Dogwood Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.
What is Dogwood Therapeutics, Inc. Common Stock's Net Debt?
Dogwood Therapeutics, Inc. Common Stock's Net Debt is -$9.6M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative expenses
IPR&D impairment———
Total operating expenses
Loss from operations
Other income (expense):
Sublease income——
Loss on debt conversion with related party——
Interest income (expense), net
Exchange (loss) gain, net
Total other income (expense)
Loss before income taxes
Deferred income tax benefit (expense)
Net loss
Net loss attributable to common stockholders
Net loss per common share, basic (in dollars per share)—
Net loss per common share, diluted (in dollars per share)—